Stryker Corporation (SYK)
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript
Stryker Corporation (NYSE:SYK ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin A. Lobo - Chairman, CEO & President Preston Wells - VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nephron Research LLC Danielle Joy Antalffy - UBS Investment Bank, Research Division Joanne Karen Wuensch - Citigroup Inc., Research Division Lawrence H.
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
Stryker (SYK) came out with quarterly earnings of $3.13 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $2.81 per share a year ago.
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)
Stryker Corporation (NYSE:SYK ) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP of Finance and IR.
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)
I am downgrading Stryker Corporation to a Hold rating with a fair value of $380 per share, despite strong performance and growth prospects. Stryker's Mako spine and shoulder applications are set to launch soon, potentially boosting its orthopedics and spine businesses. Stryker posted robust Q1 results with 10.1% organic revenue growth and 13.6% adjusted EPS growth, driven by strong topline and margin improvements.
Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
